Skip to main content
. 2021 Jul 28;7(8):e07666. doi: 10.1016/j.heliyon.2021.e07666

Figure 1.

Figure 1

Graphical-APOD (G-APOD) representation of recalled drugs. (A) Nefazodone (B) Troglitazone. The bars in red correspond to the APOD values associated with chemical properties comprising of molecular weight (W), hydrogen-bond acceptors (R), hydrogen-bond donors (G), octanol-water partition coefficient (L), and comprehensive polar surface area (S). The bar in green in the middle corresponds to the APOD value associated with the biological activity property (B). The bars in blue correspond to the predicted APOD values associated with pharmacokinetic properties comprising of absorption (A), distribution (D), metabolism (M), excretion (E), and toxicity (T). The numerical representation (N-APOD) is the height of the bars for each of the properties as a single entity in terms of a fingerprint (WRGLSBADMET). The two drugs have the N-APOD of 95083911507 and 86497812605, respectively. The benefit and risk associated values for the drug are determined separately based on the pharmacokinetic properties and represented in the APOD score. The two drugs have the APOD-score of 1–8 and 1–7, respectively.